Intelligent Bio Solutions Inc. Net Assets
Intelligent Bio Solutions Inc. net assets. Based on the latest financial reports, Intelligent Bio Solutions Inc. (INBS) has net assets worth $5.29 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.94 Million) and total liabilities ($6.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Intelligent Bio Solutions Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.29 Million |
| % of Total Assets | 44.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -19.17% |
| 10-Year Change | N/A |
| Growth Volatility | 79.52 |
Net Assets of Intelligent Bio Solutions Inc. (2017–2026)
Net assets of Intelligent Bio Solutions Inc. from 2017 to 2026. This chart illustrates how Intelligent Bio Solutions Inc.'s net assets have evolved over time, based on quarterly financial data. See Intelligent Bio Solutions Inc. (INBS) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Intelligent Bio Solutions Inc. (2017–2026)
The table below shows the annual net assets of Intelligent Bio Solutions Inc. from 2017 to 2026. For live market cap and overall valuation, see INBS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $5.29 Million | +88.03% |
| 2025-06-30 | $2.81 Million | -65.61% |
| 2024-06-30 | $8.18 Million | +121.95% |
| 2023-06-30 | $3.69 Million | -43.67% |
| 2022-06-30 | $6.55 Million | -56.38% |
| 2021-06-30 | $15.01 Million | +387.77% |
| 2020-06-30 | $-5.21 Million | -31.12% |
| 2019-06-30 | $-3.98 Million | -29.82% |
| 2018-06-30 | $-3.06 Million | +48.18% |
| 2017-06-30 | $-5.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intelligent Bio Solutions Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7465236800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Intelligent Bio Solutions Inc. Net Assets Breakdown (June 2026)
Intelligent Bio Solutions Inc. net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.06K | 0.53% |
| Other Comprehensive Income | $-546.19K | -9.91% |
| Other Components | $80.99 Million | 1469.69% |
| Total Equity | $5.51 Million | 100.00% |
Intelligent Bio Solutions Inc. Competitors by Market Cap
The table below lists competitors of Intelligent Bio Solutions Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INC S.A.
WAR:INC
|
$5.07 Million |
|
KNM Group Bhd
KLSE:7164
|
$5.08 Million |
|
Ashoka India Equity Investment Trust PLC
LSE:AIE
|
$5.08 Million |
|
Tenon Medical Inc
NASDAQ:TNON
|
$5.08 Million |
|
Versus Systems Inc
NASDAQ:VS
|
$5.07 Million |
|
Eminence Minerals Limited
AU:EMA
|
$5.07 Million |
|
Tsodilo Resources Limited
V:TSD
|
$5.06 Million |
|
Hansa Investment Company Ltd
LSE:HANA
|
$5.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intelligent Bio Solutions Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 2,996,136 to 5,510,835, a change of 2,514,699 (83.9%).
- Net loss of 12,430,975 reduced equity.
- New share issuances of 10,699,794 increased equity.
- Other comprehensive income decreased equity by 218,242.
- Other factors increased equity by 4,464,122.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.43 Million | -225.57% |
| Share Issuances | $10.70 Million | +194.16% |
| Other Comprehensive Income | $-218.24K | -3.96% |
| Other Changes | $4.46 Million | +81.01% |
| Total Change | $- | 83.93% |
Book Value vs Market Value Analysis
This analysis compares Intelligent Bio Solutions Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | $-97.90 | $1.77 | x |
| 2018-06-30 | $-72.45 | $1.77 | x |
| 2019-06-30 | $-76.41 | $1.77 | x |
| 2020-06-30 | $-73.13 | $1.77 | x |
| 2021-06-30 | $289.16 | $1.77 | x |
| 2022-06-30 | $0.45 | $1.77 | x |
| 2023-06-30 | $18.91 | $1.77 | x |
| 2024-06-30 | $26.15 | $1.77 | x |
| 2025-06-30 | $5.68 | $1.77 | x |
| 2026-06-30 | $3.74 | $1.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intelligent Bio Solutions Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -225.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -294.91%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 2.17x
- Recent ROE (-225.57%) is below the historical average (-115.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $251.25K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.58 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.88 Million |
| 2020 | 0.00% | -1967.77% | 0.08x | 0.00x | $-3.20 Million |
| 2021 | -46.74% | -355.33% | 0.09x | 1.45x | $-8.54 Million |
| 2022 | -126.89% | 0.00% | 0.00x | 1.89x | $-8.96 Million |
| 2023 | -279.86% | -845.89% | 0.12x | 2.73x | $-11.01 Million |
| 2024 | -121.94% | -326.40% | 0.23x | 1.65x | $-10.99 Million |
| 2025 | -352.75% | -346.23% | 0.37x | 2.75x | $-10.87 Million |
| 2026 | -225.57% | -294.91% | 0.35x | 2.17x | $-12.98 Million |
Industry Comparison
This section compares Intelligent Bio Solutions Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.29 Million | 0.00% | 1.26x | $5.07 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The compan… Read more